Search results
7 gru 2021 · In this large cohort of symptomatic children with CPVT, treatment with β1-selective β-blockers was independently associated with a higher risk for arrhythmic events and near-fatal arrhythmic events compared with nonselective β-blockers. This association was most evident for nadolol.
Propranolol is an oral Class II antiarrhythmic commonly used for the treatment of SVT and the prevention of recurrence in infants and children. 34 It is also prescribed for symptom management in children with palpitations secondary to premature ventricular complexes. 35 Propranolol is associated with reduced risk of cardiac arrest among ...
In this article, we reviewed the accessible literature and summarized the current guidelines on the use of beta-blockers in the treatment of cardiac arrhythmias. Keywords: β-blockers, heart failure, heart arrhythmia, COVID-19, SARS-CoV-2, propranolol. Introduction. Beta-blockers are well-established in the treatment of arrhythmias.
Short-acting β-adrenergic receptor agonists have pharmaco-logically predictable dose-related and potency-related adverse effects, including tachycardia and tremor, and they also affect serum potassium and glucose. These effects all show tolerance with continued exposure. The potential for arrhythmia is increased by comorbidity and hypoxemia.
Inhaled selective short-acting beta-2 agonists (SABA) such as albuterol and levalbuterol are recommended in national guidelines for all children with acute asthma (2). Over 85% of children who present to EDs with acute asthma are treated with albuterol (3).
Some studies have found no detectable effects of β 2-agonists on cardiac function (rate, rhythm, or electrocardiography results) by Holter monitoring in children 24 and adults, including those with COPD who were also using theophylline or who also had heart disease. 25 Arrhythmias occurred in these patients, including supraventricular ...
30 sty 2021 · Frequent premature ventricular complexes (PVCs) and asymptomatic ventricular tachycardia (VT) in children with structurally normal hearts require anti-arrhythmic drug (AAD) therapy depending on the severity of symptoms or ventricular dysfunction; however, data on efficacy in children are scarce.
